Global BC: Magic mushroom research facility opens in Princeton, B.C.

 

Magic mushrooms are now growing in Princeton, B.C., as a new mushroom research and development facility opened on Friday.

Optimi Health Corp. is a Canadian-based company that grows psilocybin-producing mushrooms and functional mushrooms for clinical trials, drug companies, and medical facilities.

Optimi Grand Opening

“We want to ramp this to full capacity, we want to make sure that we can get psilocybin medication to anybody in the world that needs it,” said Optimi Health’s head of cultivation Todd Henderson.

READ MORE: First patient in Quebec gets approval from Health Canada for magic mushroom therapy

“We have one of the largest genetic banks in the world right now, definitely in the country. It is not available for recreation; it is not available to the general public yet but who knows what the future holds.

Health Canada recently launched a program that allows physicians to request government approval for patients to access the psychedelic compound that comes from magic mushrooms.

“It can potentially treat depression, anxiety, PTSD, behavioural issues — there are tons of clinic trials going on that are showing fantastic results,” said Henderson.

The company hopes to change lives and end the stigma that surrounds the use of psychedelic mushrooms.

“Psilocybin has the potential to deal with and replace a lot of these synthetic drugs that are out there,” said Henderson.

“Just don’t be afraid of natural medicine. It was the way of our people for 1,000 years, why is it such a stigma now?”

Kelowna lab promotion provides pot profile for free

Kelowna lab promotion provides pot profile for free – May 21, 2021

Optimi Health says they are the largest GMP-grade licensed facility in Canada. The facility includes two 10,000-square-foot buildings that are adjacent to each other, and each building has 10 different growing rooms that are heavily monitored.

The facility can produce up to 4,000 pounds of mushrooms at a time and they plan to harvest at least 2,000 pounds per month.

“From the air systems to the quality of the materials we have put in, we have gone far and beyond hospital-grade so we really are a level above what a surgery or operating room would be,” said Optimi Health co-founder Bryan Safarik.

“And we have 100 per cent control, that is what makes it different. We can control the environment 100 per cent. We can repeat it and take all those analytics to help grow — and do amazing things with these mushrooms to show people what the future of medicine will really be like.”

The first growth of psilocybin mushrooms has already been completed and sold to a company in Nova Scotia.

Source: Global BC

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.